Last updated on September 2018

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Brief description of study

This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).

Clinical Study Identifier: NCT02951988

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Registry Team

Meridien Research
Bradenton, FL United States